Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Condition: Multiple Myeloma Interventions: Drug: Belantamab mafodotin; Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone) Sponsor: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials